[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370382-105":59,"doc-detail-370382-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","opportunities-and-challenges-in-antibodydrug-conjugates-for-cancer-therapy-a-new-era-for-cancer-treatment","Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy - A New Era for Cancer Treatment","","The antibody, linker, and payload components shape the therapeutic potential of antibody–drug conjugates (ADCs) for cancer treatment. ADC design is guided by antibody subclass selection, receptor affinity and pharmacokinetics, and by the choice of cleavable versus non-cleavable linkers. ADC efficacy arises from antibody-dependent mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, alongside payload-driven cytotoxicity and the bystander effect. Target antigen distribution influences both efficacy and off-target toxicities, while resistance can stem from impaired intracellular drug trafficking, abnormal lysosomal processing, and efflux via ATP-binding cassette transporters. Penetration into the tumor microenvironment and delivery to cancer cells remain major limitations, especially for solid tumors affected by vascular and binding-site barriers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/opportunities-and-challenges-in-antibodydrug-conjugates-for-cancer-therapy-a-new-era-for-cancer-treatment/370382/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/opportunities-and-challenges-in-antibodydrug-conjugates-for-cancer-therapy-a-new-era-for-cancer-treatment/370382.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What components determine the therapeutic potential of an ADC?","Question",{"text":112,"@type":113},"An ADC’s therapeutic potential depends on the antibody, linker, and payload. Antibody choice reflects receptor affinities and pharmacokinetics, while linkers can be cleavable or non-cleavable.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do ADCs kill cancer cells beyond the direct payload effect?",{"text":117,"@type":113},"ADCs also use antibody-dependent mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. The bystander effect can further extend cytotoxicity to adjacent cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main mechanisms proposed for ADC drug resistance?",{"text":121,"@type":113},"Proposed mechanisms include disrupted intracellular drug trafficking, dysfunctional lysosomal processing, and efflux of the cytotoxic molecule through ATP-binding cassette (ABC) transporters, which is especially relevant for multi-drug-resistant tumors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370382,1790652461,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Review  \nOpportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment  \nIdil Buyukgolcigezli 1, Ates Kutay Tenekeci 2,3 and Ibrahim Halil Sahin 4, *  \nAcademic Editor: Alexandre Escargueil  \nReceived: 16 February 2025  \nRevised: 10 March 2025  \nAccepted: 10 March 2025  \nPublished: 12 March 2025  \nCitation: Buyukgolcigezli, I.;  \nTenekeci, A.K.; Sahin, I.H. Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: ANew Era for Cancer Treatment. Cancers 2025, 17, 958 .  \n[https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17060958  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey; [ibuyukgolcigezli@hacettepe.edu.tr](ibuyukgolcigezli@hacettepe.edu.tr)  \n2 Department of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara 06230, Turkey; [atesktenekeci@gmail.com](atesktenekeci@gmail.com)  \n3 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA  \n4 Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA  \n* Correspondence: [sahinih@upmc.edu](sahinih@upmc.edu)  \nSimple Summary: Antibody–drug conjugates (ADCs) comprise a cytotoxic small molecule paired with a monoclonal antibody via a chemical linker. The antibody component reduces the cytotoxic effects on off-targets, making ADCs a popular area of research for the treatment of hematologic malignancies and solid tumors. This review article aims to provide an overview of ADCs in today’s cancer therapy landscape. We summarize the currently used ADCs with their cytotoxic payloads, targets, and therapeutic indications. We discuss the mechanisms of action of ADCs, as well as the associated toxicities and newly emerging mechanisms of drug resistance. We also elaborate on some of the current efforts to advance present ADC strategies, as well as opportunities for the future of ADC-based cancer therapy.  \nAbstract: The antibody, linker, and payload moieties all play a significant role in giving the ADC its unique therapeutic potential. The antibody subclass employed in ADCs is determined based on relative individual receptor affinities and pharmacokinetics. Meanwhile, the linker used in an ADC can either be cleavable or non-cleavable. ADC therapy comprises antibody-dependent mechanisms in addition to the direct cytotoxic effects of the payload. These include antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, as well as the “bystander effect”, which refers to the diffusion of a portion of the cytotoxic molecules out of the target cell, exerting its cytotoxic effect on the adjacent cells. Target antigens of ADCs are expected to be expressed on the membranes of the cancer cells facing the external matrix, although new approaches utilize antigens regarding tumor-associated cells, the tumor microenvironment, or the tumor vasculature. These target antigens of ADCs not only determine the efficacy of these agents but also impact the off-targets and related adverse effects. The majority of ADC-related toxicities are associated with off-targets. The proposed mechanisms of ADC resistance include disrupted intracellular drug trafficking, dysfunctional lysosomal processing, and the efflux of the cytotoxic molecule via ATP-binding cassette (ABC) transporters. The latter mechanism is especially prominent for multi-drug-resistant tumors. An important limitation of ADCs is the penetration of the conjugate into the tumor microenvironment and their delivery to target cancer cells. Cancerous ","cbCaiooM1l4vcl4X","https://ap.wps.com/l/cbCaiooM1l4vcl4X","pdf",1258760,"English","# Introduction\n## Key historical foundations and early ADC concepts\n# ADC Structure and Mechanisms\n## Antibody, linker, and payload roles\n## Antibody-dependent cytotoxicity and bystander effect\n# Target Antigens and Toxicities\n## On-target expression and off-target adverse effects\n# ADC Resistance Mechanisms\n## Trafficking, lysosomal processing, and drug efflux\n# Clinical Challenges in Solid Tumors\n## Tumor microenvironment penetration and binding-site barrier\n# Future Directions\n## Reducing toxicity, overcoming resistance, and expanding combinations","[{\"question\":\"What components determine the therapeutic potential of an ADC?\",\"answer\":\"An ADC’s therapeutic potential depends on the antibody, linker, and payload. Antibody choice reflects receptor affinities and pharmacokinetics, while linkers can be cleavable or non-cleavable.\"},{\"question\":\"How do ADCs kill cancer cells beyond the direct payload effect?\",\"answer\":\"ADCs also use antibody-dependent mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. The bystander effect can further extend cytotoxicity to adjacent cells.\"},{\"question\":\"What are the main mechanisms proposed for ADC drug resistance?\",\"answer\":\"Proposed mechanisms include disrupted intracellular drug trafficking, dysfunctional lysosomal processing, and efflux of the cytotoxic molecule through ATP-binding cassette (ABC) transporters, which is especially relevant for multi-drug-resistant tumors.\"}]","Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy - A New Era for Cancer Treatment | PDF",1790188259,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa5a9921c4c1eb6c818f45b66f4bd7cf.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96b2f1a0fbddb4885f10ba79585dbf5b.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b225eadfd528c09bec17384633476ab2.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/484bdff60fc882887f33ab5e17b301ca.webp",980,1385]